Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

NCT02787447 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Lung Adenocarcinoma

Interventions

DRUG: TKI
RADIATION: Thoracic Hypofractionated Radiotherapy
DRUG: Thymosin Alpha 1

Sponsor

First People's Hospital of Hangzhou